Trade Names:TobraDex- Ointment 0.1% dexamethasone/0.3% tobramycin- Ophthalmic Suspension 0.1% dexamethasone/0.3% tobramycin
Tobramycin inhibits bacterial protein synthesis, causing death; dexamethasone suppresses inflammatory response.
Superficial bacterial ocular infection or risk of bacterial ocular infection; inflammatory conditions of palpebral and bulbar conjunctiva, cornea, and anterior segment of globe where inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution of edema and inflammation; chronic anterior uveitis and corneal injury from chemical, radiation, thermal burns, or penetration of foreign bodies; risk of superficial ocular infection is high or is an expectation, or potentially dangerous numbers of bacteria will be present in the eye.
Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva; mycobacterial infection of the eye; fungal diseases of ocular structure; hypersensitivity to a component of the product.
Ophthalmic Start with 1 or 2 drops instilled into conjunctival sac(s) every 4 to 6 h during first 24 to 48 h; dosage may be increased to 1 or 2 drops every 2 h.OintmentAdults and Children 2 yr of age and older
Ophthalmic Apply small amount (approximately 0.5-inch ribbon) into conjunctival sac(s) up to 3 or 4 times daily.
Store at controlled room temperature. Keep suspension upright. Keep container tightly closed
None well documented.
None well documented.
Localized ocular toxicity (eg, lid itching, swelling, conjunctival erythema); elevated IOP (with possible glaucoma); infrequent optic nerve damage; posterior subcapsular cataract formation; delayed wound healing; secondary infection (eg, corneal fungal infections); secondary bacterial ocular infection.
Category C .
Excreted in breast milk.
Safety and efficacy not established (solution). Safety and efficacy not established in children younger than 2 yr of age (ointment).
Sensitivity to topically applied aminoglycosides and cross-sensitivity to other aminoglycosides may occur.
Consider possibility of fungal infections with long-term steroid dosing; prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.
Punctate keratitis, erythema, increased lacrimation, edema, lid itching.
Copyright © 2009 Wolters Kluwer Health.